Diffusion Pharmaceuticals Inc. - FORM 10-K - EX-32.2 - EXHIBIT 32.2 - March 25, 2016

Attached files

file filename
10-K - FORM 10-K - Diffusion Pharmaceuticals Inc.dffn20151231_10k.htm
EX-3.3 - EXHIBIT 3.3 - Diffusion Pharmaceuticals Inc.ex3-3.htm
EX-4.7 - EXHIBIT 4.7 - Diffusion Pharmaceuticals Inc.ex4-7.htm
EX-3.4 - EXHIBIT 3.4 - Diffusion Pharmaceuticals Inc.ex3-4.htm
EX-21.1 - EXHIBIT 21.1 - Diffusion Pharmaceuticals Inc.ex21-1.htm
EX-23.1 - EXHIBIT 23.1 - Diffusion Pharmaceuticals Inc.ex23-1.htm
EX-31.2 - EXHIBIT 31.2 - Diffusion Pharmaceuticals Inc.ex31-2.htm
EX-10.3 - EXHIBIT 10.3 - Diffusion Pharmaceuticals Inc.ex10-3.htm
EX-31.1 - EXHIBIT 31.1 - Diffusion Pharmaceuticals Inc.ex31-1.htm
EX-10.24 - EXHIBIT 10.24 - Diffusion Pharmaceuticals Inc.ex10-24.htm
EX-32.1 - EXHIBIT 32.1 - Diffusion Pharmaceuticals Inc.ex32-1.htm

Exhibit 32.2

 

CERTIFICATION OF CEO PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Diffusion Pharmaceuticals Inc. (the “Company”) on Form 10-K for the year ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ben Shealy, Senior Vice President – Finance and Treasurer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

 

  

/s/ Ben Shealy

 

 

 

Ben Shealy

 

 

 

Senior Vice President – Finance and Treasurer

 

   

March 25, 2016

  

 

Diffusion Pharmaceuticals Inc. Reports